[go: up one dir, main page]

UY29777A1 - Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. - Google Patents

Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.

Info

Publication number
UY29777A1
UY29777A1 UY29777A UY29777A UY29777A1 UY 29777 A1 UY29777 A1 UY 29777A1 UY 29777 A UY29777 A UY 29777A UY 29777 A UY29777 A UY 29777A UY 29777 A1 UY29777 A1 UY 29777A1
Authority
UY
Uruguay
Prior art keywords
agomelatine
depression
patients
treatment
medicines
Prior art date
Application number
UY29777A
Other languages
English (en)
Inventor
Bruno Delalleau
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36200255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of UY29777A1 publication Critical patent/UY29777A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
UY29777A 2005-09-09 2006-08-31 Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. UY29777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509207A FR2890562B1 (fr) 2005-09-09 2005-09-09 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime

Publications (1)

Publication Number Publication Date
UY29777A1 true UY29777A1 (es) 2006-10-31

Family

ID=36200255

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29777A UY29777A1 (es) 2005-09-09 2006-08-31 Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.

Country Status (25)

Country Link
US (1) US20070060655A1 (es)
EP (2) EP2295050A1 (es)
JP (1) JP2007077148A (es)
KR (2) KR20070029608A (es)
CN (1) CN1927193B (es)
AP (1) AP2008004379A0 (es)
AR (1) AR056063A1 (es)
AU (1) AU2006209372A1 (es)
BR (1) BRPI0603762A (es)
CA (1) CA2558762A1 (es)
EA (1) EA014288B1 (es)
FR (1) FR2890562B1 (es)
GE (1) GEP20094602B (es)
GT (1) GT200600409A (es)
MA (1) MA28506B1 (es)
MX (1) MXPA06010233A (es)
NO (1) NO20064050L (es)
NZ (1) NZ549726A (es)
PE (1) PE20070333A1 (es)
SG (1) SG146451A1 (es)
TW (1) TW200800148A (es)
UA (1) UA81573C2 (es)
UY (1) UY29777A1 (es)
WO (1) WO2007028905A1 (es)
ZA (1) ZA200607531B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918372B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2918370B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013119605A1 (en) 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Promoting sleep using at1 receptor blockers
CN102552211B (zh) * 2012-02-16 2013-07-17 福建广生堂药业股份有限公司 一种阿戈美拉汀的制剂组合物及其制备方法
ES2645223T3 (es) 2013-06-06 2017-12-04 Zentiva, K.S. Formulaciones de agomelatina que comprenden agomelatina en forma de co-cristales
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
CN103655499B (zh) * 2013-12-23 2015-07-22 天津泰普药品科技发展有限公司 一种稳定的晶x型阿戈美拉汀片剂及其制备方法
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
CN104523639B (zh) * 2014-12-11 2017-03-22 扬子江药业集团四川海蓉药业有限公司 一种阿戈美拉汀片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7645905B2 (en) * 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
US20070060655A1 (en) 2007-03-15
ZA200607531B (en) 2008-05-28
FR2890562B1 (fr) 2012-10-12
FR2890562A1 (fr) 2007-03-16
GEP20094602B (en) 2009-02-10
UA81573C2 (en) 2008-01-10
MA28506B1 (fr) 2007-04-03
EP2295050A1 (fr) 2011-03-16
SG146451A1 (en) 2008-10-30
MXPA06010233A (es) 2007-03-08
AU2006209372A1 (en) 2007-03-29
JP2007077148A (ja) 2007-03-29
KR20080103043A (ko) 2008-11-26
TW200800148A (en) 2008-01-01
EP1762237A1 (fr) 2007-03-14
GT200600409A (es) 2007-04-30
AR056063A1 (es) 2007-09-19
BRPI0603762A (pt) 2007-05-15
CA2558762A1 (fr) 2007-03-09
HK1100481A1 (en) 2007-09-21
WO2007028905A1 (fr) 2007-03-15
AP2008004379A0 (en) 2008-04-30
KR20070029608A (ko) 2007-03-14
NO20064050L (no) 2007-03-12
PE20070333A1 (es) 2007-06-02
EA200601449A1 (ru) 2007-04-27
CN1927193B (zh) 2011-01-05
NZ549726A (en) 2008-03-28
CN1927193A (zh) 2007-03-14
EA014288B1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
EA202091999A2 (ru) Применение ингибиторов dpp iv
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
GT200800117A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y uso
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
UY33219A (es) Cetoenoles cíclicos para terapias
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2007002324A1 (es) Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular.
UY31131A1 (es) "oxazolidinonas sustituidas y su uso
PA8800601A1 (es) Productos quimioterapeuticos cristalinos
DK2155179T3 (da) Axomadol til smertebehandling arthrose
CR9426A (es) Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares
AR061618A1 (es) Formas de dosificacion unitaria de temozolomida
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
CL2008002195A1 (es) Compuestos derivados de espiro ciclopentano; composicion farmaceutica que comprende a dichos compuestos; su proceso de preparacion; y su uso para tratar trastornos del sueño.
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
UY29247A1 (es) Amidas de ácido pirazindicarboxílico y su uso
DOP2005000168A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas